Who is sponsoring NCT02085655?

NCT02085655 is sponsored by Huiqiang Huang.

What drugs are being tested in NCT02085655?

Interventions in NCT02085655: pegaspargase, Gemcitabine, Oxaliplatin, Methotrexate, Dexamethasone, Thalidomide.

What condition does NCT02085655 study?

NCT02085655 studies Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type.

Is NCT02085655 still recruiting?

NCT02085655 is currently status unknown. Last updated 15 March 2021.

Last reviewed 2021-03-15 · How we verify

NCT02085655

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Status unknown Phase 3 Last updated 15 March 2021

What this trial tests

Phase 3 trial testing pegaspargase in Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type in 264 participants. Status unknown.

Timeline

25 April 2013

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Huiqiang Huang
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	264
Start date	25 April 2013
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across China

Drugs / interventions tested

pegaspargase — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
Methotrexate
Dexamethasone (dexamethasone) — full drug profile →
Thalidomide (THALIDOMIDE) — full drug profile →

Conditions studied

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type — all drugs for Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type →

Sponsor

Huiqiang Huang — full company profile →

Who can join

Adults 18 to 75, any sex, with Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J, Vacchelli E, Aranda F, Castoldi F, et al · · 2015 · cited 238× · PMID 26137404 · DOI 10.1080/2162402x.2015.1008866
PEGylated therapeutics in the clinic.
Gao Y, Joshi M, Zhao Z, Mitragotri S. · · 2024 · cited 133× · PMID 38193121 · DOI 10.1002/btm2.10600
First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-up.
Wang L, Wang ZH, Chen XQ, Wang KF, et al · · 2015 · cited 52× · PMID 26622621 · DOI 10.3892/ol.2015.3327
Novel target and treatment agents for natural killer/T-cell lymphoma.
Tian XP, Cao Y, Cai J, Zhang YC, et al · · 2023 · cited 19× · PMID 37480137 · DOI 10.1186/s13045-023-01483-9
Advances and challenges of immunotherapies in NK/T cell lymphomas.
He L, Chen N, Dai L, Peng X. · · 2023 · cited 12× · PMID 38026157 · DOI 10.1016/j.isci.2023.108192
Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440
Extranodal NK/T-cell lymphoma: an update of the molecular characterization of the tumor and microenvironment, and its clinical implications.
Chan WL, Hue SS, Deng L, Leong SM, et al · · 2025 · cited 5× · PMID 41132165 · DOI 10.1016/j.lanwpc.2025.101550

Verify or expand the search:

Other trials of pegaspargase

Trials testing the same drug.

NCT01700946 — Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma · Phase 2 · completed

Other Huiqiang Huang trials

Trials by the same sponsor.

NCT04796857 — Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL · Phase 1, PHASE2 · unknown
NCT04514393 — Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma · Phase 2 · unknown
NCT04476459 — Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL · Phase 1, PHASE2 · unknown
NCT04058470 — Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma · Phase 1, PHASE2 · unknown
NCT04246359 — Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02085655 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huiqiang Huang
Last refreshed: 15 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02085655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing